赛升药业：达格列净二甲双胍缓释片注册上市许可申请获受理

Core Viewpoint - The announcement by Sai Sheng Pharmaceutical regarding the acceptance of the production registration application for Dapagliflozin Metformin Extended-Release Tablets marks a significant step in expanding its product portfolio in the diabetes treatment market [1] Group 1: Company Developments - Sai Sheng Pharmaceutical's subsidiary, Sai Er Biological, has received a notice from the National Medical Products Administration regarding the acceptance of the production registration application for Dapagliflozin Metformin Extended-Release Tablets [1] - The combination of SGLT-2 inhibitor Dapagliflozin and Metformin is developed by AstraZeneca and was approved by the FDA in 2014 [1] Group 2: Industry Insights - SGLT-2 inhibitors function through a non-insulin-dependent mechanism, reducing glucose reabsorption in the kidneys and promoting glucose excretion through urine, which helps lower blood sugar levels [1] - The combination of SGLT-2 inhibitors with Metformin has shown better glycemic control and lower side effects [1]